TW348217B - Stable antibody solution and stabilization of antibody - Google Patents

Stable antibody solution and stabilization of antibody

Info

Publication number
TW348217B
TW348217B TW082110685A TW82110685A TW348217B TW 348217 B TW348217 B TW 348217B TW 082110685 A TW082110685 A TW 082110685A TW 82110685 A TW82110685 A TW 82110685A TW 348217 B TW348217 B TW 348217B
Authority
TW
Taiwan
Prior art keywords
antibody
stabilization
stable
solution
concentration
Prior art date
Application number
TW082110685A
Other languages
English (en)
Inventor
Yoichi Sawayanagi
Original Assignee
Doujin Iyaku Kako Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Doujin Iyaku Kako Kk filed Critical Doujin Iyaku Kako Kk
Application granted granted Critical
Publication of TW348217B publication Critical patent/TW348217B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW082110685A 1992-12-17 1993-12-16 Stable antibody solution and stabilization of antibody TW348217B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4337478A JP2553445B2 (ja) 1992-12-17 1992-12-17 抗体の安定化方法

Publications (1)

Publication Number Publication Date
TW348217B true TW348217B (en) 1998-12-21

Family

ID=18309028

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082110685A TW348217B (en) 1992-12-17 1993-12-16 Stable antibody solution and stabilization of antibody

Country Status (7)

Country Link
US (1) US5602234A (zh)
EP (1) EP0602601B1 (zh)
JP (1) JP2553445B2 (zh)
KR (1) KR100263398B1 (zh)
CA (1) CA2111603A1 (zh)
DE (1) DE69325634T2 (zh)
TW (1) TW348217B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069697A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Colorimetrically assessing peptide characteristics
WO2006079091A1 (en) * 2005-01-24 2006-07-27 Mallinckrodt Inc. Methods of providing long-term stability to biocompatible optical dyes and bodily fluids
JP4965302B2 (ja) * 2007-03-26 2012-07-04 東洋紡績株式会社 抗体の安定化方法
US8003314B2 (en) 2007-04-16 2011-08-23 Diagnostic Hybrids, Inc. Methods for direct fluorescent antibody virus detection in liquids
WO2015125501A1 (ja) * 2014-02-24 2015-08-27 国立大学法人名古屋大学 タンパク質凍結保存用保護剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1180957A (en) * 1967-12-13 1970-02-11 Sterling Winthrop Group Ltd Improvements in or relating to Immunological Reagents for Diagnostic Techniques.
DE2364792A1 (de) * 1973-01-15 1974-07-18 South African Inventions Verfahren zum reinigen von gammaglobulin
JPS56145222A (en) * 1980-04-28 1981-11-11 Toshiyuki Hamaoka Improved antibody and its preparation
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US4650772A (en) * 1984-08-09 1987-03-17 Abbott Laboratories Monoclonal antibody stabilization
JPS62289523A (ja) * 1986-06-09 1987-12-16 Green Cross Corp:The 静脈投与用免疫グロブリンの加熱処理方法
DE69029203T2 (de) * 1990-07-18 1997-04-10 Dojin Iyaku Kako Co Ltd Reagens zur diagnose von mycoplasma pneumonie
JPH04173799A (ja) * 1990-11-05 1992-06-22 Sanyo Chem Ind Ltd プロラクチン水溶液

Also Published As

Publication number Publication date
US5602234A (en) 1997-02-11
EP0602601A2 (en) 1994-06-22
DE69325634T2 (de) 1999-12-09
JPH06186230A (ja) 1994-07-08
CA2111603A1 (en) 1994-06-18
EP0602601B1 (en) 1999-07-14
KR940013537A (ko) 1994-07-15
DE69325634D1 (de) 1999-08-19
KR100263398B1 (ko) 2000-08-01
JP2553445B2 (ja) 1996-11-13
EP0602601A3 (en) 1995-05-24

Similar Documents

Publication Publication Date Title
NZ332625A (en) Concentrated antibody preparation containing greater than 100 mg/ml of the antibody
SE8206168L (sv) Peptidpreparat
CA2135062A1 (en) Pharmaceutical and Other Dosage Forms
KR950005324A (ko) 인슐린 제제
ES8603271A1 (es) Un metodo de producir una composicion de interleuquina-2
UA43348C2 (uk) Водна фармацевтична композиція, що включає фактор росту нерва (варіанти) та ліофілізований фармацевтичний склад
AU2478888A (en) Plasma and recombinant protein formulations in low ionic strength media
ATE103932T1 (de) Fusionsprotein bestehend aus gm-csf und il-3.
CA2099782A1 (fr) Derive de la 5h-pyrrolo[3,4-b] pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent
AU6405790A (en) Preparations containing colestyramine for reducing lipid levels
AU7249198A (en) Substantially pure zonulin, a physiological modulator of mammalian tight junctions
EP1224940A8 (de) Flüssige Interferon-Beta Formulierungen
AU1179795A (en) Improved immunogenic compositions against human gastrin 17
AU4326693A (en) Monoclonal antibodies to glycoprotein p
DE69420872D1 (de) Hgh enthaltende pharmazeutische zubereitungen
TW348217B (en) Stable antibody solution and stabilization of antibody
AU537173B2 (en) Stabilization of peroxidase
AU5749198A (en) Crystallisation of proteins
TR200003521T2 (tr) Yeniden-kombine-edilen insan interferonu beta-1a (IFN-beta-1a) formülasyonu.
AU8375891A (en) Antioxidant system based on a basic amino acid in combination with a tocopherol or derivative thereof and a nonthiolated polypeptide, and compositions containing the same
ES2173879T3 (es) Procedimiento para la preparacion de conjugados a base de un participe especifico en la fijacion y de una proteina que contiene hidratos de carbono
GB9107434D0 (en) Peptide-based assay
AU625831B2 (en) Solubilization of t-pa
ES2089091T3 (es) Complejos que contienen acidos s(+)-fenilalcanoicos y acidos alfa-hidroalcanoicos.
ATE170292T1 (de) Nachweis von antibiotika